A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with PD-L1+ Non-Small Cell Lung Cancer

A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

An open-label Phase I dose finding trial with BI 891065 alone and in combination with BI 754091 to characterise safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy in patients with advanced and/or metastatic malignancies

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study Of Chemoradiation Versus Chemoradiation Plus Atezolizumab

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inh

A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung

A Prospective Longitudinal Collection of Peripheral Blood to Support the Validation of Biomarkers as an Aid in Monitoring Disease in Patients with all Stages of Lung Cancer

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

A Phase 1 Study to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses and treatment intensification of a vaccine-based immunotherapy Regimen-2 (VBIR-2) (PF-06936308) for advanced non-small cell lung cancer and metastatic tripl

A STUDY TO EVALUATE A PANEL OF BLOOD BIOMARKERS FOR USE IN PATIENTS UNDERGOING EVALUATION FOR LUNG CANCER, ONC-LN-04